Literature DB >> 32629849

Diagnostic Potential of IgG and IgA Responses to Mycobacterium tuberculosis Antigens for Discrimination among Active Tuberculosis, Latent Tuberculosis Infection, and Non-Infected Individuals.

Ji Yeon Lee1,2, Byoung-Jun Kim2, Hyeon-Kyoung Koo3, Junghyun Kim1, Jee-Min Kim1, Yoon-Hoh Kook2, Bum-Joon Kim2.   

Abstract

Tuberculosis remains a major public health problem. Conventional tests are inadequate to distinguish between active tuberculosis (ATB) and latent tuberculosis infection (LTBI). We measured antibody responses to Mycobacterium tuberculosis antigens (Mycobacterium tuberculosis chorismate mutase (TBCM), antigen 85B (Ag85B), early secreted antigen-6 (ESAT-6), and culture filtrate protein-10 (CFP-10) in ATB, LTBI, and non-infected (NI) individuals. Serum immunoglobulin G (IgG) and immunoglobulin A (IgA) levels were measured and the QuantiFERON-TB Gold In-Tube assay was used to diagnose LTBI. IgG levels against TBCM were significantly higher in LTBI than NI subjects. IgG and IgA levels against Ag85B and IgG levels against CFP-10 were significantly higher in ATB, followed by LTBI, and then NI. When the ATB group was subdivided, IgG levels against Ag85B and CFP-10 were significantly higher in each subgroup compared with those in LTBI and NI groups. Positive correlation trends between interferon-gamma and IgG levels against Ag85B, TBCM, and CFP-10 and IgA levels against Ag85B in LTBI and NI subjects were observed. Age- and sex-adjusted models showed that IgG against TBCM and CFP-10 was independently related to LTBI diagnosis, and IgG against Ag85B was independently related to the diagnosis of ATB and could distinguish between LTBI and ATB. Overall, IgG antibody responses to TBCM, Ag85B, and CFP-10 can discriminate among ATB, LTBI, and NI groups.

Entities:  

Keywords:  biomarkers; diagnosis; serology; tuberculosis

Year:  2020        PMID: 32629849     DOI: 10.3390/microorganisms8070979

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  4 in total

1.  Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis.

Authors:  Nadege Nziza; Deniz Cizmeci; Leela Davies; Edward B Irvine; Wonyeong Jung; Brooke A Fenderson; Marwou de Kock; Willem A Hanekom; Kees L M C Franken; Cheryl L Day; Tom H M Ottenhoff; Galit Alter
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

2.  Potential of Mycobacterium tuberculosis chorismate mutase (Rv1885c) as a novel TLR4-mediated adjuvant for dendritic cell-based cancer immunotherapy.

Authors:  Hyein Jeong; So-Young Lee; Hyejun Seo; Dong Hyun Kim; Duhyung Lee; Bum-Joon Kim
Journal:  Oncoimmunology       Date:  2022-01-20       Impact factor: 8.110

3.  Diagnostic Potential of the Serological Response to Synthetic Peptides from Mycobacterium tuberculosis Antigens for Discrimination Between Active and Latent Tuberculosis Infections.

Authors:  Zaida Araujo; Jacobus H de Waard; Milena Camargo; Juan Ernesto Lopez-Ramos; Carlos Fernández de Larrea; Magnolia Vanegas; Manuel A Patarroyo
Journal:  Int J Pept Res Ther       Date:  2022-05-03       Impact factor: 2.191

4.  Monitoring IgG against Mycobacterium tuberculosis proteins in an Asian elephant cured of tuberculosis that developed from long-term latency.

Authors:  Satoshi Ishikawa; Yuriko Ozeki; Satomi Suga; Yasuhiko Mukai; Haruka Kobayashi; Erina Inouchi; Shaban A Kaboso; Gebremichal Gebretsadik; Desak Nyoman Surya Suameitria Dewi; Akihito Nishiyama; Yoshitaka Tateishi; Hayato Takihara; Shujiro Okuda; Shiomi Yoshida; Naoaki Misawa; Sohkichi Matsumoto
Journal:  Sci Rep       Date:  2022-03-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.